Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03732820
Title Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

prostate adenocarcinoma

Therapies

Abiraterone

Abiraterone + Olaparib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.